Patents by Inventor Sailesh Haresh Daswani

Sailesh Haresh Daswani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Low endotoxin fucan compositions, systems, and methods
    Patent number: 11938145
    Abstract: Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are disclosed. Methods and systems for removing or reducing the amount of endotoxins from a starting fucan composition are also disclosed.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: March 26, 2024
    Assignee: ARC Medical Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • HIGH-MOLECULAR-WEIGHT FUCANS FOR TREATING FIBROUS ADHESIONS AND OTHER DISEASES AND CONDITIONS
    Publication number: 20230140869
    Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.
    Type: Application
    Filed: July 27, 2022
    Publication date: May 11, 2023
    Applicant: ARC Medical Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun
  • Highly purified and/or modified fucan compositions for the treatment of fibrous adhesions
    Patent number: 11642368
    Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 9, 2023
    Assignee: ARC Medical Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • Highly purified fucans for the treatment of fibrous adhesions
    Patent number: 11628183
    Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: April 18, 2023
    Assignee: ARC Medical Ine.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • Highly sulfated fucans for the treatment of fibrous adhesions
    Patent number: 11446326
    Abstract: A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: September 20, 2022
    Assignee: ARC Medical Devices
    Inventors: Christopher Michael Kevin Springate, Sailesh Haresh Daswani
  • High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions
    Patent number: 11419891
    Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: August 23, 2022
    Assignee: ARC Medical Devices Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun
  • SYSTEMS AND METHODS FOR TANGENTIAL FLOW FILTRATION OF VISCOUS COMPOSITIONS
    Publication number: 20220226779
    Abstract: Apparatus, methods, systems, etc., for the tangential flow filtration (TFF) of viscous compositions including viscous fluids, solutions, gels, pastes, creams and suspensions with viscosities greater than 10 cP, 20 cP, 50 cP or 100 cP. The methods, etc., provide enhanced mixing of the viscous compositions in their storage vessels by extracting the input composition from different depths in the storage vessels to reduce or eliminate vertical concentration gradients.
    Type: Application
    Filed: March 5, 2020
    Publication date: July 21, 2022
    Applicant: ARC Medical Devices Inc.
    Inventors: Ian Millet, Sailesh Haresh Daswani
  • METHOD FOR PREDICTING A MOLECULAR WEIGHT DISTRIBUTION OF A BIOPOLYMER BLEND
    Publication number: 20210391036
    Abstract: Methods, systems etc., for predicting and/or consistently obtaining uniform biopolymer compositions by blending a plurality of input biopolymer compositions with different molecular weight distributions, the blending based on concentration data as a function of molecular weight for the plurality of input biopolymer compositions.
    Type: Application
    Filed: March 5, 2020
    Publication date: December 16, 2021
    Applicant: ARC Medical Devices Inc.
    Inventors: Sailesh Haresh Daswani, Hoi Ting Wong
  • LOW ENDOTOXIN FU CAN COMPOSITIONS, SYSTEMS AND METHODS
    Publication number: 20210299159
    Abstract: Low endotoxin fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising less than about 0.2, 0.18, 0.1, 0.01, 0.001, or 0.0005 endotoxin units (EU) per milligram of the fucan are disclosed. Methods and systems for removing or reducing the amount of endotoxins from a starting fucan composition are also disclosed.
    Type: Application
    Filed: July 24, 2019
    Publication date: September 30, 2021
    Applicant: ARC Medical Devices Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • HIGHLY PURIFIED AND/OR MODIFIED FUCAN COMPOSITIONS FOR THE TREATMENT OF FIBROUS ADHESIONS
    Publication number: 20210290660
    Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
    Type: Application
    Filed: July 24, 2019
    Publication date: September 23, 2021
    Applicant: ARC Medical Devices Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • HIGHLY PURIFIED RICANS FOR THE TREATMENT OF FIBROUS ADHESIONS
    Publication number: 20210290659
    Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
    Type: Application
    Filed: July 24, 2019
    Publication date: September 23, 2021
    Applicant: ARC Medical Devices Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • HIGH-MOLECULAR-WEIGHT FUCANS FOR TREATING FIBROUS ADHESIONS AND OTHER DISEASES AND CONDITIONS
    Publication number: 20210292441
    Abstract: High-molecular-weight fucan compositions comprising a therapeutically effective, medically acceptable fucan in a composition comprising wherein the fucan, for example, has a molecular weight distribution in which more than 60% w/w of the composition has a molecular weight above 100 kDa.
    Type: Application
    Filed: July 24, 2019
    Publication date: September 23, 2021
    Applicant: ARC Medical Devices Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun
  • HIGHLY SULFATED FUCANS FOR THE TREATMENT OF FIBROUS ADHESIONS
    Publication number: 20210290658
    Abstract: A highly-sulfated modified fucan comprising a therapeutically effective, medically acceptable fucan in a composition comprising a sulfate to fucose molar ratio of greater than or equal to about 1.2, 1.81 or 1.9 and/or a sulfate to fucose plus galactose molar ratio of greater than or equal to about 1.1, 1.2 or 1.3.
    Type: Application
    Filed: July 24, 2019
    Publication date: September 23, 2021
    Applicant: ARC Medical Devices Inc.
    Inventors: Christopher Michael Kevin Springate, Bryan Young, Sailesh Haresh Daswani